Philip Jonsson

13.6k citations

41 papers · 2.8k indexed · 2 hit papers · h-index 27

Impact in

Cancer Research top 2%
- Cancer Genomics and Diagnostics
- Cancer-related molecular mechanisms research
Genetics top 2%
- Estrogen and related hormone effects
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Cancer Research 20
- Cancer Genomics and Diagnostics 9
- MicroRNA in disease regulation 4
Oncology 18
- HER2/EGFR in Cancer Research 3
- Cancer-related Molecular Pathways 3

Co-authors: Cecilia Williams Alison M. Schram Matthew T. Chang Alexander Drilon Michael F. Berger Ahmet Zehir David M. Hyman David B. Solit
Journals: Molecular Endocrinology (4 papers)Cancer Research (4 papers)JCO Precision Oncology (2 papers)Journal of Clinical Oncology (2 papers)Oncogene (2 papers)
Partner nations: United States Sweden Germany

In The Last Decade

Philip Jonsson

41 papers receiving 2.8k citations

Hit Papers

align trajectories log scale

Genome doubling shapes the evolution and prognosis of advanced cancers 2018 · 343 citations

Peers

Countries citing papers authored by Philip Jonsson

Since Specialization

Citations

This map shows the geographic impact of Philip Jonsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Jonsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Jonsson more than expected).

Fields of papers citing papers by Philip Jonsson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Jonsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Jonsson. The network helps show where Philip Jonsson may publish in the future.

Co-authors

The 25 scholars most cited alongside Philip Jonsson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philip Jonsson Line = papers co-authored together Philip Jonsson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy npj Precision Oncology ·Charlotte S. Walmsley, Philip Jonsson, Michael L. Cheng, Sean M. McBride, Yorck Leschber, H. Alberto Vargas, Vincent P. Laudone, Barry S. Taylor, Rajya Kappagantula, Priscilla Baez, Allison L. Richards, 正人岩淵, D. S. Perera, Michael F. Berger, David B. Solit, Christine A. Iacobuzio–Donahue, Howard I. Scher, Mark T.A. Donoghue, Wassim Abida, Alison M. Schram	2024	7
2	STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts Cancer Discovery ·Luís F. Dias da Silva, David J. St. Jean, Enrique Rayo, Brendon Ladd, Brendan J. Hilbert, Weixue Wang, F. Hampton Roy, Hugo Pelliza, Gregory V. Kryukov, Natasja Brooijmans, Atsushi ICHIKI, Philip Jonsson, Daniel Marquês Franco, Srinivas Gunti, Erica L. Jackson, Marcus D. Goncalves, Darrin D. Stuart	2023	41
3	Phase and context shape the function of composite oncogenic mutations Nature ·Alexander N. Gorelick, Francisco J. Sánchez‐Rivera, Yanyan Cai, Craig M. Bielski, Evan Biederstedt, Philip Jonsson, Allison L. Richards, Neil Vasan, Alexander Penson, Noah D. Friedman, Yu-Jui Ho, Timour Baslan, Chaitanya Bandlamudi, Maurizio Scaltriti, Nikolaus Schultz, Scott W. Lowe, Ed Reznik, Barry S. Taylor	2020	26
4	A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers Clinical Cancer Research ·Paul K. Paik, Rachel K. Kim, Linda S. Ahn, Andrew J. Plodkowski, Ai Ni, Mark T.A. Donoghue, Philip Jonsson, Miguel A. Villalona‐Calero, Kenneth Ng, Daniel C. McFarland, John J. Fiore, Afsheen N. Iqbal, Juliana Eng, Mark G. Kris, Charles M. Rudin	2020	10
5	A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF V600E-Mutant Brain Tumor Cancer Discovery ·Jiawan Wang, Zhan Yao, Philip Jonsson, Amy N. Allen, Alice Can Ran Qin, Sharmeen Uddin, Ira J. Dunkel, Mary Petriccione, Katia Manova, Sofia Haque, Marc K. Rosenblum, David J. Pisapia, Neal Rosen, Barry S. Taylor, Christine A. Pratilas	2018	49
6	Genome doubling shapes the evolution and prognosis of advanced cancers Nature Genetics ·Craig M. Bielski, Ahmet Zehir, Alexander Penson, Mark T.A. Donoghue, Walid K. Chatila, Joshua Armenia, Matthew T. Chang, Alison M. Schram, Philip Jonsson, Chaitanya Bandlamudi, Pedram Razavi, Gopa Iyer, Mark E. Robson, Zsofia K. Stadler, Nikolaus Schultz, José Baselga, David B. Solit, David M. Hyman, Michael F. Berger, Barry S. Taylor Hit paper breakdown →	2018	343
7	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer Cancer Cell ·Craig M. Bielski, Mark T.A. Donoghue, Mayur Gadiya, Aphrothiti J. Hanrahan, Helen Won, Matthew T. Chang, Philip Jonsson, Alexander Penson, Alexander N. Gorelick, Christopher Harris, Alison M. Schram, Aijazuddin Syed, Ahmet Zehir, Paul B. Chapman, David M. Hyman, David B. Solit, Kevin Shannon, Sarat Chandarlapaty, Michael F. Berger, Barry S. Taylor	2018	59
8	Insufficient antibody validation challenges oestrogen receptor beta research Nature Communications ·Sandra Andersson, Mårten Sundberg, Nuša Pristovšek, Ahmed Atef Ibrahim, Philip Jonsson, Borbala Katona, Carl-Magnus Clausson, Agata Zieba, Margareta Ramström, Ola Söderberg, Cecilia Williams, Anna Asplund	2017	184
9	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes Cell stem cell ·Catherine C. Coombs, Ahmet Zehir, Sean M. Devlin, Ashwin Kishtagari, Aijazuddin Syed, Philip Jonsson, David M. Hyman, David B. Solit, Mark E. Robson, José Baselga, Maria E. Arcila, Marc Ladanyi, Martin S. Tallman, Ross L. Levine, Michael F. Berger Hit paper breakdown →	2017	521
10	Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance Nature Reviews Clinical Oncology ·Alison M. Schram, Matthew T. Chang, Philip Jonsson, Alexander Drilon	2017	226
11	Transforming Biomarker Development with Exceptional Responders Trends in cancer ·Philip Jonsson, Barry S. Taylor	2017	3
12	AP-1 Is a Key Regulator of Proinflammatory Cytokine TNFα-mediated Triple-negative Breast Cancer Progression Journal of Biological Chemistry ·Yichun Qiao, Huan He, Philip Jonsson, Indranil Sinha, Chunyan Zhao, Karin Dahlman‐Wright	2016	96
13	Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade Annals of Oncology ·Y. Y. Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Yaelle Tuvy, Nancy Bouvier, Jamie C. Riches, Ritika Kundra, Geoffrey Y. Ku, Jaclyn F. Hechtman, David P. Kelsen, Laura H. Tang, David H. Ilson, Efsevia Vakiani, Zsofia K. Stadler, Margaret K. Callahan, David B. Solit, Michael F. Berger, Barry S. Taylor, Nikolaus Schultz	2016	3
14	Lxr regulates lipid metabolic and visual perception pathways during zebrafish development Molecular and Cellular Endocrinology ·Caroline Pinto, John D′Emilio, Catherine W. McCollum, Anne Riu, Philip Jonsson, W. Marquardt, Eric C. Swindell, Е С Хайдукова, Patrick Balaguer, Maria Bondesson, Jan-Åke Gustafsson	2015	33
15	RING finger protein 31 promotes p53 degradation in breast cancer cells Oncogene ·Jiawei Zhu, Chunyan Zhao, Ting Zhuang, Philip Jonsson, Indranil Sinha, Cecilia Williams, Staffan Strömblad, Karin Dahlman‐Wright	2015	52
16	Genome-wide Profiling of AP-1–Regulated Transcription Provides Insights into the Invasiveness of Triple-Negative Breast Cancer Cancer Research ·Chunyan Zhao, Yichun Qiao, Philip Jonsson, Jian Wang, Xu Li, Pegah Rouhi, Indranil Sinha, Yihai Cao, Cecilia Williams, Karin Dahlman‐Wright	2014	104
17	miR‐206 inhibits cell migration through direct targeting of the actin‐binding protein Coronin 1C in triple‐negative breast cancer Molecular Oncology ·Jun Wang, Efrosini Tsouko, Philip Jonsson, Jonas Bergh, Johan Hartman, Eylem Aydoğdu, Cecilia Williams	2014	76
18	The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor α and modulates estrogen-stimulated breast cancer cell proliferation Oncogene ·Jian Zhu, Chunyan Zhao, (unknown), Ting Zhuang, Philip Jonsson, Ning Liang, Cecilia Williams, Chin‐Yo Lin, Yingying Qiao, Kazem Zendehdel, Staffan Strömblad, Eckardt Treuter, Karin Dahlman‐Wright	2014	80
19	Coexposure to Phytoestrogens and Bisphenol A Mimics Estrogenic Effects in an Additive Manner Toxicological Sciences ·Cristián Camilo Colorado Castillo, Caroline Pinto, Philip Jonsson, Trang Nguyen-Vu, Marchela Pandelova, Anne Riu, Karl‐Werner Schramm, Daniel V. Samarov, Jan-Ακε Gustafsson, Maria Bondesson, Cecilia Williams	2013	48
20	Support of a bi-faceted role of estrogen receptor β (ERβ) in ERα-positive breast cancer cells Endocrine Related Cancer ·Philip Jonsson, Cristián Camilo Colorado Castillo, Cecilia Williams	2013	35

About Philip Jonsson

Philip Jonsson is a scholar working on Cancer Research, Oncology, Genetics, Genetics and Behavioral Neuroscience, having authored 41 papers that have together received 2.8k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (9 papers), Estrogen and related hormone effects (8 papers), Glioma Diagnosis and Treatment (4 papers), MicroRNA in disease regulation (4 papers), Cholesterol and Lipid Metabolism (3 papers), Ubiquitin and proteasome pathways (3 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer-related Molecular Pathways (3 papers). The work is most often cited by research in Cancer Research (902 citations), Genetics (407 citations), Hematology (377 citations), Oncology (773 citations) and Molecular Biology (1.4k citations). Philip Jonsson has collaborated with scholars based in United States, Sweden and Germany. Frequent co-authors include Cecilia Williams, Alison M. Schram, Matthew T. Chang, Alexander Drilon, Michael F. Berger, Ahmet Zehir, David M. Hyman, David B. Solit, Jan-Ακε Gustafsson and Karin Dahlman‐Wright. Their work appears in journals such as Molecular Endocrinology, Cancer Research, JCO Precision Oncology, Journal of Clinical Oncology and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact